No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	enzalutamide capsule Sensitive: A1 - Approval enzalutamide capsule Sensitive : A1	enzalutamide capsule Sensitive: A1 - Approval enzalutamide capsule Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	darolutamide Sensitive: A1 - Approval darolutamide Sensitive : A1	darolutamide Sensitive: A1 - Approval darolutamide Sensitive : A1
AR splice variant 7	Prostate Cancer	AR splice variant 7	Prostate Cancer	enzalutamide capsule Resistant: A2 - Guideline enzalutamide capsule Resistant : A2	enzalutamide capsule Resistant: A2 - Guideline enzalutamide capsule Resistant : A2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	bicalutamide Sensitive: A2 - Guideline bicalutamide Sensitive : A2	bicalutamide Sensitive: A2 - Guideline bicalutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	bicalutamide + goserelin acetate Sensitive: A2 - Guideline bicalutamide + goserelin acetate Sensitive : A2	bicalutamide + goserelin acetate Sensitive: A2 - Guideline bicalutamide + goserelin acetate Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	goserelin acetate + flutamide Sensitive: A2 - Guideline goserelin acetate + flutamide Sensitive : A2	goserelin acetate + flutamide Sensitive: A2 - Guideline goserelin acetate + flutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	bicalutamide + triptorelin Sensitive: A2 - Guideline bicalutamide + triptorelin Sensitive : A2	bicalutamide + triptorelin Sensitive: A2 - Guideline bicalutamide + triptorelin Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	triptorelin + flutamide Sensitive: A2 - Guideline triptorelin + flutamide Sensitive : A2	triptorelin + flutamide Sensitive: A2 - Guideline triptorelin + flutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	leuprolide acetate + bicalutamide Sensitive: A2 - Guideline leuprolide acetate + bicalutamide Sensitive : A2	leuprolide acetate + bicalutamide Sensitive: A2 - Guideline leuprolide acetate + bicalutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	leuprolide acetate + flutamide Sensitive: A2 - Guideline leuprolide acetate + flutamide Sensitive : A2	leuprolide acetate + flutamide Sensitive: A2 - Guideline leuprolide acetate + flutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	bicalutamide + histrelin acetate Sensitive: A2 - Guideline bicalutamide + histrelin acetate Sensitive : A2	bicalutamide + histrelin acetate Sensitive: A2 - Guideline bicalutamide + histrelin acetate Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	histrelin acetate + flutamide Sensitive: A2 - Guideline histrelin acetate + flutamide Sensitive : A2	histrelin acetate + flutamide Sensitive: A2 - Guideline histrelin acetate + flutamide Sensitive : A2
AR amplification	Prostate Cancer	AR amplification	Prostate Cancer	enzalutamide capsule Resistant: B - Late Trials enzalutamide capsule Resistant : B	enzalutamide capsule Resistant: B - Late Trials enzalutamide capsule Resistant : B
PTEN mutation	Prostate Cancer	PTEN mutation	Prostate Cancer	bicalutamide Sensitive: B - Late Trials bicalutamide Sensitive : B	bicalutamide Sensitive: B - Late Trials bicalutamide Sensitive : B
TP53 deletion	Prostate Cancer	TP53 deletion	Prostate Cancer	enzalutamide capsule Resistant: B - Late Trials enzalutamide capsule Resistant : B	enzalutamide capsule Resistant: B - Late Trials enzalutamide capsule Resistant : B
RB1 deletion	Prostate Cancer	RB1 deletion	Prostate Cancer	enzalutamide capsule Resistant: B - Late Trials enzalutamide capsule Resistant : B	enzalutamide capsule Resistant: B - Late Trials enzalutamide capsule Resistant : B
BRCA2 deletion	Prostate Cancer	BRCA2 deletion	Prostate Cancer	enzalutamide capsule Sensitive: B - Late Trials enzalutamide capsule Sensitive : B	enzalutamide capsule Sensitive: B - Late Trials enzalutamide capsule Sensitive : B
CD8 expression	Prostate Cancer	CD8 expression	Prostate Cancer	atezolizumab + enzalutamide capsule Sensitive: B - Late Trials atezolizumab + enzalutamide capsule Sensitive : B	atezolizumab + enzalutamide capsule Sensitive: B - Late Trials atezolizumab + enzalutamide capsule Sensitive : B
PD-L1 overexpression	Prostate Cancer	PD-L1 overexpression	Prostate Cancer	atezolizumab + enzalutamide capsule Sensitive: B - Late Trials atezolizumab + enzalutamide capsule Sensitive : B	atezolizumab + enzalutamide capsule Sensitive: B - Late Trials atezolizumab + enzalutamide capsule Sensitive : B
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	talazoparib + enzalutamide capsule Sensitive: B - Late Trials talazoparib + enzalutamide capsule Sensitive : B	talazoparib + enzalutamide capsule Sensitive: B - Late Trials talazoparib + enzalutamide capsule Sensitive : B
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	enzalutamide capsule Sensitive: C2 – Inclusion Criteria enzalutamide capsule Sensitive : C2	enzalutamide capsule Sensitive: C2 – Inclusion Criteria enzalutamide capsule Sensitive : C2
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	enzalutamide capsule Sensitive: C2 – Inclusion Criteria enzalutamide capsule Sensitive : C2	enzalutamide capsule Sensitive: C2 – Inclusion Criteria enzalutamide capsule Sensitive : C2
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2
AR-V7 positive	Prostate Cancer	AR-V7 positive	Prostate Cancer	enzalutamide capsule Resistant: C2 – Inclusion Criteria enzalutamide capsule Resistant : C2	enzalutamide capsule Resistant: C2 – Inclusion Criteria enzalutamide capsule Resistant : C2
AR F877L	Prostate Cancer	AR F877L	Prostate Cancer	enzalutamide capsule Resistant: C3 – Early Trials enzalutamide capsule Resistant : C3	enzalutamide capsule Resistant: C3 – Early Trials enzalutamide capsule Resistant : C3
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3
PLIN2 expression	Salivary Gland Cancer	PLIN2 expression	Salivary Gland Cancer	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3
AR F876L	Prostate Cancer	AR F876L	Prostate Cancer	enzalutamide capsule Resistant: C3 – Early Trials enzalutamide capsule Resistant : C3	enzalutamide capsule Resistant: C3 – Early Trials enzalutamide capsule Resistant : C3
PTEN expression	Salivary Gland Cancer	PTEN expression	Salivary Gland Cancer	bicalutamide Sensitive: C3 – Early Trials bicalutamide Sensitive : C3	bicalutamide Sensitive: C3 – Early Trials bicalutamide Sensitive : C3
MSI-H/dMMR	Prostate Cancer	MSI-H/dMMR	Prostate Cancer	pembrolizumab + enzalutamide capsule Sensitive: C3 – Early Trials pembrolizumab + enzalutamide capsule Sensitive : C3	pembrolizumab + enzalutamide capsule Sensitive: C3 – Early Trials pembrolizumab + enzalutamide capsule Sensitive : C3
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	enzalutamide capsule Resistant: C3 – Early Trials enzalutamide capsule Resistant : C3	enzalutamide capsule Resistant: C3 – Early Trials enzalutamide capsule Resistant : C3
AR expression	Prostate Cancer	AR expression	Prostate Cancer	enzalutamide capsule Resistant: C3 – Early Trials enzalutamide capsule Resistant : C3	enzalutamide capsule Resistant: C3 – Early Trials enzalutamide capsule Resistant : C3

Androgen receptor inhibitor

Androgen receptor inhibitor

Associations(88)

Associations
(88)